Bio (IBIO) announced data from a non-GLP non-human primate pharmacokinetics study suggesting IBIO-600, the company’s novel lead asset and a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

1 Multiple trials, including hundreds of obese/overweight women in the menopausal/postmenopausal age group, reflect weight loss of at least 5% with three months of semaglutide treatment.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Semaglutide use associated with increased risk for NAION at the 2-, 3-, and 4-year time point from the index date.

As cancer progressed, mice still pursued easy rewards but quickly abandoned tasks requiring greater effort. Meanwhile, we ...